Connect with us

Biotech

Curevac invests millions in the production of its corona vaccine

In the fight against coronavirus, the Tübingen-based biotech company Curevac plans to massively expand its production capacities. That was announced by a Curevac spokesperson on Thursday, October 29th. The company hopes to be able to offer an applicable vaccine by mid 2021, the spokesperson said. Curevac will receive $294 million (€252 million) from the government.

Eva Wesley

Published

on

Companies around the world are working flat out on a corona vaccine. The Tübingen-based company Curevac also has a vaccine in the pipeline. In order to produce as many doses as possible and as quickly as possible, the biotech specialist is now also massively expanding its production capacities.

The Tübingen-based biotech company Curevac plans to considerably expand its production capacity in the coming years. Currently, depending on the vaccine dosage, more than 100 million doses per year can be produced. The corresponding plants should be “cloned” in the coming months, a Curevac spokesperson told Merkur.de on Thursday, October 29th.

Read more about Curevac plans to expand production capabilities for its coronavirus vaccine and read the latest business news with the Born2Invest mobile app.

Curevac builds new production facility for at least one billion doses per year

In addition, a completely new production plant is being built. It is scheduled to start operations in 2022 and, depending on the quantity of vaccine, will be able to produce at least one billion doses per year. The building for this is already in place. The spokesman said that the necessary equipment would now be installed. Curevac plans to invest $87.5 million (€75 million) in the production facilities alone. The biotech specialist had secured a loan from the European Investment Bank in July to finance the investment.

Curevac expects a finished COVID-19 vaccine by mid 2021

It was only at the end of September that Curevac started the second phase of testing its corona vaccine candidate. The Tübingen-based company plans to start Phase IIB/III in the current quarter. Curevac recently announced that it plans to test its vaccine in different dosages on approximately 20,000 to 30,000 volunteers. This is expected to take several months. It is hoped to be able to offer an applicable vaccine by mid 2021, the spokesperson said.

SEE ALSO  Bitcoin crosses $2,500 level; 2017 gains up over 160%

Federal Research Minister Anja Karliczek (CDU) also expects a widely applicable vaccine against the coronavirus in the middle of next year. She assumes that by then “broad sections of the population can be vaccinated”, Karliczek said in Berlin on Thursday. The pressure is increasing. On Wednesday alone, the Robert Koch Institute had registered 4,000 new cases of infection.

In order to accelerate the development of a vaccine, the German government had set up a special program to support the development of the vaccine. Curevac is to receive $294 million (€252 million), the Mainz-based company Biontech $437 million (€375 million). In addition, IDT Biologika is now also being considered. The Dessau-based company is to receive $133 million (€114 million) in funding.

Curevac only started Phase I testing of its corona vaccine in June. The basic tolerability of a vaccine is tested on a group of 10 to 30 people. In Phase II, the immune response after injection is tested and the optimal dose is determined. The size of the test groups is usually extended to 50 to 500 persons.

In the final Phase III test with more than 10,000 subjects, the protective effect of the vaccine is controlled. To accelerate development, Phase II and Phase III may overlap. This is also planned for Curevac.

Corona vaccine: Curevac focuses on low dosage and thus better tolerability

Similar to the Mainz-based competitor Biontech, for example, the Tübingen-based company also specializes in the development of messenger nucleic acids (mRNA). In this novel approach, messengers are supposed to bring genetic blueprints for the production of unimaginably tiny amounts of antigens into the cells. The proteins produced should trigger a defense reaction of the immune system, which should then also protect the body against viruses such as the coronavirus SARS-CoV-2.

SEE ALSO  Congress is in favor of funding rural America

Curevac focuses on mRNA with comparatively low doses. The company hopes that this will lead to particularly good tolerability in the test persons. In addition, a low dosage enables considerable volume advantages per batch during subsequent production. *Merkur.de is part of the Ippen Digital network

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in kreiszetung.de, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.